The long term goal of the project is to help eliminate and slow the progression of joint destruction in osteoarthritis.
The innovative research approach led by Dr. Loeser will utilize a high-throughput, cell-based functional drug screening platform for identifying compounds that inhibit chondrocyte catabolic activity.
The core project team includes:
- Kenneth Pearce, PhD; Co-PI: Professor in the Eshelman School of Pharmacy and Director of Lead Discovery and Characterization in the Center for Integrative Chemical Biology and Drug Discovery
- Philip Coryell, PhD: Post-doctoral Research Associate in the Loeser lab, based in the UNC Thurston Arthritis Research Center
FastTraCS is a pilot grant program within NCTraCS. The mission of FastTraCS is to accelerate existing and novel healthcare technology towards the marketplace, to ultimately benefit patients in North Carolina and beyond.
The project described was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR002489. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.